Biotechnology Taxation Law In Russia.

1. Introduction

Biotechnology taxation law in Russia refers to the legal and fiscal framework governing the taxation of biotechnology companies, pharmaceutical manufacturers, genetic research institutions, medical biotechnology laboratories, agricultural biotechnology enterprises, bioengineering businesses, and organisations engaged in scientific research and development (R&D).

Russia does not have one separate, comprehensive statute called the Biotechnology Taxation Act. Instead, biotechnology taxation is regulated through general tax legislation, particularly the Tax Code of the Russian Federation, together with legislation governing pharmaceuticals, medical products, scientific research, intellectual property, innovation, and special economic zones.

The principal objective is to balance government revenue collection with investment in scientific research, technological innovation, domestic pharmaceutical production, and biotechnology development.

The taxation framework affects:

Pharmaceutical and vaccine manufacturing.

Biotechnology research and development.

Genetic engineering and genomic research.

Stem-cell and regenerative medicine enterprises.

Agricultural biotechnology and genetically modified organisms.

Medical devices and diagnostic technologies.

Biotechnology patents and licensing.

Imports and exports of biological materials and research equipment.

Foreign investment in biotechnology enterprises.

An important distinction is that tax benefits are not automatically available merely because a business describes itself as a biotechnology company. Eligibility generally depends on the company's legal structure, activities, products, location, accreditation and compliance with specific statutory requirements.

2. Main legal framework

The principal legislation includes the following:

LegislationRelevance to biotechnology taxation
Tax Code, Part I (Federal Law No. 146-FZ, 1998)Tax administration, audits, liability and taxpayer rights
Tax Code, Part II (Federal Law No. 117-FZ, 2000)Profit tax, VAT, property tax and R&D deductions
Federal Law No. 127-FZ of 1996Scientific and technological research
Federal Law No. 86-FZ of 1996Medicines and pharmaceutical regulation
Federal Law No. 61-FZ of 2010Circulation of medicines
Federal Law No. 488-FZ of 2014Industrial policy and industrial development
Federal Law No. 116-FZ of 2005Special economic zones and associated tax regimes
Federal Law No. 478-FZ of 2023Development of small technology companies

The Tax Code is the central instrument. Its provisions determine whether a biotechnology enterprise can deduct research expenditure, obtain VAT exemptions, use reduced regional tax rates or benefit from special investment arrangements.

3. Corporate profit taxation

Corporate profit tax is one of the most important taxes affecting Russian biotechnology companies.

Under Chapter 25 of the Tax Code, companies generally pay tax on taxable profits calculated by deducting legally recognised expenses from taxable income.

Standard federal and regional framework

The general corporate profit tax rate increased to 25% from 1 January 2025.

For biotechnology companies, taxable income may include:

Sales of vaccines and pharmaceutical products.

Licensing income from patented biotechnology.

Royalties from genetic-engineering technologies.

Contract research income.

Sales of diagnostic equipment.

Commercialisation of laboratory discoveries.

Biotechnology manufacturing and consultancy services.

Deductible expenditure may include qualifying employee salaries, laboratory materials, equipment depreciation, contract research and other documented business expenses.

Example: A Russian biotechnology company develops a new diagnostic test. It receives RUB 100 million in taxable revenue and has RUB 60 million in deductible expenses.

Its taxable profit is RUB 40 million.

At the general 25% rate, the illustrative corporate profit tax is RUB 10 million, before considering any special incentives or adjustments.

4. Research and development tax incentives

One of the most significant provisions for biotechnology enterprises is Article 262 of the Russian Tax Code.

It governs the treatment of expenses incurred in scientific research and experimental design and development (R&D).

Biotechnology research covered by this framework may include:

Genetic engineering.

Vaccine development.

Drug discovery.

Molecular biology.

Synthetic biology.

Stem-cell research.

Bioinformatics.

Agricultural biotechnology.

Development of diagnostic technologies.

Development of new biological materials.

4.1 Deduction of R&D expenses

Article 262 allows qualifying research expenditure to be recognised for corporate profit tax purposes.

Eligible expenditure can include:

Salaries of scientists and laboratory researchers.

Social insurance contributions associated with qualifying salaries.

Laboratory materials and research supplies.

Depreciation of qualifying research equipment.

Contracted scientific research.

Certain acquired intellectual property rights used exclusively for R&D.

A particularly important feature is that qualifying R&D expenditure may be recognised even when the research produces no positive result, subject to the statutory conditions.

This is important because biotechnology research frequently involves unsuccessful experiments, failed clinical-development programmes and discoveries that cannot be commercially exploited.

4.2 Double deduction for qualifying research

Article 262(7) provides for the recognition of qualifying R&D expenditure using a coefficient of 2.

This can effectively allow eligible expenditure to be recognised at twice its actual amount for tax purposes.

However, this is not an automatic benefit for all biotechnology research. The research must satisfy the applicable statutory requirements, including the relevant approved R&D list and reporting requirements, subject to special rules for qualifying small technology companies.

Example:

A biotechnology enterprise spends RUB 20 million on eligible research into a new vaccine.

If the research qualifies for the double-expense mechanism:

Actual expenditure: RUB 20 million.

Tax-deductible amount: RUB 40 million.

Additional deduction: RUB 20 million.

The additional deduction reduces taxable profit, not the tax bill directly.

Article 262 also contains special rules concerning the capitalisation and amortisation of intellectual property generated by R&D.

Consultant Plus+1

 

5. Value-added tax (VAT) and biotechnology products

VAT is another major component of biotechnology taxation.

The general Russian VAT rate increased to 22% from 1 January 2026. Certain qualifying medicines and medical goods may receive preferential treatment, including the applicable 10% rate or statutory exemptions.

The relevant provisions are principally contained in Articles 149 and 164 of the Tax Code.

5.1 Pharmaceutical products

The preferential VAT treatment of medicines depends on their legal classification and inclusion in the relevant statutory lists.

It does not apply automatically to every biological product or laboratory-developed substance.

Products potentially requiring examination include:

Vaccines.

Biological medicines.

Certain therapeutic proteins.

Medicinal biotechnology products.

Certain registered pharmaceutical preparations.

5.2 Scientific research services

Article 149 provides exemptions for specified research and development activities.

In particular, qualifying R&D financed from designated public funds and qualifying research performed by educational and scientific organisations under commercial agreements can fall within the statutory exemption.

Article 149(16.1) also covers specified R&D and technological-development activities involving the creation or improvement of products and technologies.

A commercial biotechnology laboratory must therefore establish that its services satisfy the statutory description rather than assume that all scientific services are VAT-exempt.

USPTO+1

 

5.3 Imported biological equipment

Biotechnology enterprises importing laboratory equipment, diagnostic instruments, reagents and research materials must examine:

Import VAT.

Customs duties.

Tariff classification.

Customs valuation.

Available exemptions.

Whether the equipment is imported for qualifying scientific or medical purposes.

The tax treatment depends on the specific goods and their customs classification.

6. Taxation of biotechnology patents and intellectual property

Biotechnology companies frequently generate valuable intellectual property, including:

Genetic-engineering patents.

Pharmaceutical formulations.

DNA sequencing technologies.

Vaccine manufacturing processes.

Laboratory-developed biological methods.

Biotechnological software and databases.

Plant varieties and biological inventions.

The tax treatment of these assets is particularly important because biotechnology companies may earn more from licensing and commercialising patents than from manufacturing products.

6.1 Patent income

Income from licensing biotechnology patents is generally taxable under the applicable corporate profit tax rules.

The relevant provisions include Articles 249, 250, 257 and 262 of the Tax Code.

Article 257 deals with depreciable intangible assets. Where qualifying exclusive rights are obtained through research, they may be recognised as intangible assets and amortised under the applicable rules.

6.2 Royalty taxation

Royalty payments received by Russian biotechnology companies may constitute taxable income.

International licensing arrangements can also raise issues concerning:

Withholding tax.

Double taxation agreements.

Transfer pricing.

Beneficial ownership.

Tax residency.

Related-party transactions.

Payments for technology transfers.

A foreign biotechnology company licensing a vaccine-production technology from a Russian enterprise must examine the relevant domestic tax rules and any applicable international tax treaty.

6.3 Transfer pricing

Articles 105.1–105.3 of the Tax Code govern related-party transactions and transfer pricing.

These provisions are relevant when biotechnology groups transfer patents, biological materials, manufacturing technologies or research services between associated companies.

For example, a Russian pharmaceutical subsidiary may purchase genetic-engineering technology from its foreign parent company. The tax authorities may examine whether the transaction price corresponds to the applicable arm's-length requirements.

7. Taxation of biotechnology startups and small technology companies

Russia's innovation policy provides several mechanisms that may benefit qualifying biotechnology startups.

However, the availability of a tax advantage depends on the particular legal regime.

7.1 Small technology companies

Federal Law No. 478-FZ of 2023 establishes the framework for developing small technology companies.

A qualifying biotechnology company included in the relevant register may receive access to certain support mechanisms.

An important development is the treatment of qualifying small technology companies under Article 262(9).

Under the amended provision, qualifying registered small technology companies may use the double R&D expenditure coefficient when forming the initial value of certain patented intangible assets, even where the research does not satisfy the ordinary approved-list requirement, subject to the statutory conditions.

This is significant for companies developing patented genetic technologies, diagnostic inventions and biological manufacturing processes.

Consultant Plus+1

 

7.2 Special economic zones

The Russian Special Economic Zones framework under Federal Law No. 116-FZ of 2005 can provide qualifying residents with fiscal advantages.

Potentially relevant zones and innovation locations include:

Skolkovo Innovation Center.

Dubna Special Economic Zone.

Technopolis Moscow.

Depending on the applicable regime, eligible biotechnology enterprises may obtain:

Reduced regional corporate profit tax rates.

Property tax relief.

Land tax relief.

Customs-related benefits.

Special investment and innovation support.

These advantages are conditional and must be assessed against the specific zone's legislation and resident requirements.

8. Property taxation and laboratory infrastructure

Biotechnology enterprises often own expensive scientific infrastructure.

Examples include:

High-containment biological laboratories.

Genome sequencing machines.

Bioreactors.

Vaccine manufacturing facilities.

Cold-storage systems.

Medical diagnostic equipment.

Pharmaceutical production machinery.

Property taxation is governed primarily by Chapter 30 of the Tax Code.

The treatment depends on the nature of the property, its accounting classification, cadastral valuation where applicable, and regional legislation.

For example, a biotechnology manufacturer establishing a vaccine production facility may need to examine whether its industrial buildings and equipment qualify for any available regional property tax relief.

A company should not assume that laboratory equipment is automatically exempt merely because it is used for scientific research.

9. Payroll taxation and social insurance

Biotechnology enterprises employ highly specialised personnel, including:

Molecular biologists.

Geneticists.

Pharmaceutical scientists.

Clinical researchers.

Bioinformatics specialists.

Laboratory technicians.

Biomedical engineers.

Employers must comply with personal income tax withholding obligations and statutory insurance contribution requirements.

These obligations are particularly relevant to biotechnology startups because scientific personnel may represent a substantial proportion of operating expenditure.

Qualifying salary expenditure and associated insurance contributions can also form part of eligible R&D expenses under Article 262.

The company must maintain appropriate employment records and evidence of the time employees actually spend on qualifying research activities.

10. Agricultural biotechnology taxation

Agricultural biotechnology has a distinct position in Russia's taxation framework.

Relevant business activities include:

Plant breeding.

Seed development.

Agricultural genetic research.

Biological fertiliser production.

Microbial crop protection.

Livestock biotechnology.

Veterinary biological products.

Some agricultural enterprises may qualify for the Unified Agricultural Tax (ЕСХН) under Chapter 26.1 of the Tax Code.

However, eligibility depends on the statutory agricultural-producer requirements and the proportion and nature of qualifying agricultural income.

A biotechnology company manufacturing biological pesticides or genetically improved seeds cannot automatically use this regime simply because its products serve agricultural purposes.

11. Pharmaceutical and vaccine manufacturing taxation

Pharmaceutical biotechnology is an especially important area because it combines scientific research, industrial manufacturing and public-health regulation.

Russian pharmaceutical companies may be subject to:

Corporate profit tax.

VAT.

Property tax.

Employment-related taxes and contributions.

Customs duties and import taxes.

Transfer-pricing rules.

The tax treatment of pharmaceutical products must be distinguished from their regulatory approval.

For example, registration of a biological medicine does not itself create a general corporate tax exemption.

Likewise, a vaccine may qualify for a preferential VAT rate if it meets the relevant statutory classification and documentation requirements.

The company must separately comply with the medicines legislation and tax legislation.

12. Important judicial decisions and case laws

Russian biotechnology taxation does not have a large, clearly established body of reported judgments dealing exclusively with biotechnology companies. Nevertheless, Russian courts have decided several important disputes involving R&D expenditure, VAT treatment, scientific services and the commercialisation of research results.

These decisions provide useful principles for biotechnology taxation.

Case 1: Presidium of the Supreme Arbitration Court, Resolution No. 16067/11, 15 March 2012

Important R&D and VAT precedent

Subject: Research and development services supplied to a foreign customer.

The dispute concerned a Russian corporation that developed computer software for a foreign organisation. The company treated its work as applied scientific research and argued that the relevant transaction should not be subject to Russian VAT because the place of supply was outside Russia.

The tax authority challenged the company's treatment of the revenue.

The Presidium examined the character of the services, the transfer of intellectual property rights and the rules determining the place of supply under Article 148 of the Tax Code.

Legal significance for biotechnology:

The decision is relevant by analogy to biotechnology companies providing:

Genetic sequencing services to foreign clients.

Contract research services.

Bioinformatics development.

Pharmaceutical research.

Laboratory technology development.

The central lesson is that the contractual and legal nature of the transaction matters. A company must establish whether it is providing research services, transferring intellectual property rights or supplying another taxable service.

Source:

Федеральные арбитражные суды

 

Case 2: Eighteenth Arbitration Appeal Court, Case No. 18АП-1052/2009, 3 March 2009

Subject: Deductibility of unsuccessful research expenditure.

The dispute concerned expenditure on scientific research and the development of a pilot drying installation. The research did not produce a positive result.

The taxpayer argued that the expenditure could be recognised under Article 262 of the Tax Code.

The court considered the applicable statutory version and the timing of completion of the research.

It accepted that the taxpayer could recognise the qualifying expenditure under the amended rules, allowing the actual costs to be included in other expenses over the relevant three-year period.

Legal significance for biotechnology:

The reasoning is relevant to:

Failed vaccine research.

Unsuccessful genetic engineering experiments.

Failed drug-development projects.

Experimental biological manufacturing.

Unsuccessful laboratory technology development.

A failed research project does not automatically mean that the expenditure is non-deductible.

However, the company must prove that the activities genuinely constituted qualifying research and that the expenditure was properly documented.

Source:

ГАРАНТ

 

Case 3: AO TVEL and OOO Materik — Case No. А44-1329/2019

Subject: VAT deductions involving research and development services.

This dispute concerned the separation of research and development services from transactions involving the sale of goods.

The courts upheld the tax authorities' challenges to the VAT deductions in the circumstances described in the reported analysis.

The relevant considerations included:

Whether the research services were separate from the goods.

Whether the engineering model was independently marketable.

Whether the research expenditure was properly connected to the underlying transactions.

Whether the taxpayer had correctly classified the contractual operations.

Legal significance for biotechnology:

This case is particularly relevant to businesses that combine research and manufacturing.

For example, a biotechnology enterprise may:

Develop a biological product.

Manufacture that product.

License the manufacturing process.

Sell the finished product to a foreign customer.

The company must properly distinguish the tax treatment of its research services, intellectual property transfers and product sales.

Source:

DOI

 

Case 4: Russian Constitutional Court, Resolution No. 17-P, 3 June 2014

Subject: VAT deductions involving suppliers using special tax regimes.

The Constitutional Court considered the circumstances in which purchasers may deduct VAT amounts associated with transactions involving suppliers operating under special tax regimes.

The decision is relevant to the treatment of VAT deductions and the legal consequences of transactions with suppliers who are not ordinary VAT payers.

Legal significance for biotechnology:

A biotechnology company purchasing laboratory equipment, research services or manufacturing inputs from a supplier operating under a special tax regime must examine the supplier's actual VAT status and the conditions for deductibility.

The ruling is not a biotechnology-specific judgment, but its VAT principles may be relevant to biotechnology supply chains.

Source:

Pepeliaev Group

 

Case 5: Russian Supreme Court, Judicial Board for Economic Disputes, 27 November 2017

Case Nos.:

А56-35772/2016, No. 307-КГ17-9857.

А56-42572/2016, No. 307-КГ17-12461.

Subject: VAT deductions involving transactions exempt under Article 149.

These cases concerned VAT invoices issued in connection with activities that were exempt from VAT.

The Supreme Court's approach confirmed that the legal consequences of incorrectly charging VAT on exempt transactions require careful examination. The Court recognised the relevance of VAT deductions in the circumstances addressed in its decisions.

Legal significance for biotechnology:

The decisions are useful when considering:

VAT treatment of scientific research.

Exempt research services.

Purchases connected with exempt biotechnology activities.

VAT invoices issued by research contractors.

A biotechnology enterprise should not assume that input VAT is automatically deductible simply because it has received an invoice. The nature of the transaction and the statutory exemption must be examined.

Source:

Pepeliaev Group

 

Summary of judicial principles

Judicial decisionPrincipal legal issueBiotechnology relevance
No. 16067/11 (2012)Foreign research services and VATCross-border biotechnology R&D
No. 18АП-1052/2009 (2009)Unsuccessful research expenditureFailed scientific experiments
No. А44-1329/2019R&D services and VAT deductionsResearch combined with manufacturing
No. 17-P (2014)VAT treatment of special-regime suppliersResearch procurement
Nos. 307-КГ17-9857 and 307-КГ17-12461 (2017)VAT deductions and exempt transactionsVAT treatment of scientific services

Academic qualification: These are general Russian tax precedents or analogous decisions, not judgments establishing a special biotechnology tax doctrine. Their application to a biotechnology dispute depends on the relevant facts and the version of the Tax Code in force.

13. Cross-border biotechnology taxation

International biotechnology transactions create additional tax issues.

Russian biotechnology companies may cooperate with foreign universities, pharmaceutical manufacturers, laboratories, investors and research organisations.

Common transactions include:

Export of biological medicines.

Import of laboratory equipment.

Licensing of genetic technologies.

International clinical research.

Transfer of pharmaceutical patents.

Cross-border genomic research.

International contract manufacturing.

13.1 Double taxation

International licensing and research contracts may raise questions concerning withholding tax and double taxation agreements.

The applicable treaty position must be examined carefully, including any suspension, termination or modification of treaty benefits.

13.2 Transfer pricing

Related-party biotechnology transactions must be examined under Articles 105.1–105.3.

Particular attention should be given to intellectual property valuation because biotechnology patents and proprietary manufacturing processes can have substantial economic value.

13.3 Import and export taxation

The treatment of imported biological products and exported pharmaceutical goods depends on customs classification, applicable VAT rules and the nature of the transaction.

Exports of qualifying goods may receive zero-rated VAT treatment under Article 164, subject to the relevant statutory requirements and evidence.

Cross-border research services require separate analysis under Articles 148 and 149.

14. Biotechnology taxation reforms and emerging developments in Russia

An important recent development occurred on 25 February 2026, when Russia's Ministry of Industry and Trade reported that government agencies had agreed on a draft roadmap for developing the bioeconomy.

The proposed roadmap includes:

Developing tax preferences for biotechnology enterprises.

Reducing the financial burden on biotechnology manufacturers.

Improving the regulatory classification of bioeconomy products.

Developing import and tariff measures.

Strengthening the domestic biotechnology industry.

These measures indicate that biotechnology taxation is an emerging area of Russian industrial and economic policy. However, proposed tax preferences should not be confused with benefits already enacted in the Tax Code.

Industry and Trade Ministry

 

Emerging taxation challenges

1. Synthetic biology taxation: Determining whether synthetic biological products qualify for existing pharmaceutical, industrial or research tax benefits.

2. Genetic engineering taxation: Determining whether genetic engineering expenditure qualifies for enhanced R&D deductions.

3. AI-driven biotechnology: Distinguishing expenditure on AI software, bioinformatics and biological experimentation.

4. Stem-cell research: Determining the VAT treatment of research services and commercial medical applications.

5. Biomanufacturing: Establishing whether biological manufacturing activities qualify for regional investment incentives.

6. Biotechnology intellectual property: Valuing patents, genetic technologies and proprietary biological processes for tax purposes.

7. Failed clinical development: Establishing the deductibility of unsuccessful scientific and development expenditure.

15. Tax compliance and legal responsibilities

Biotechnology companies must maintain proper financial, scientific and regulatory documentation.

Important compliance requirements include:

Compliance areaRequired documentation
R&D expenditureResearch contracts and technical reports
Employee expensesPayroll and employee time records
Laboratory expensesInvoices and procurement records
Patent expenditurePatent registrations and licensing agreements
VATVAT invoices and transaction documentation
Pharmaceutical manufacturingProduct registration and manufacturing records
International transactionsTransfer-pricing documentation where required
Tax incentivesEvidence of eligibility and statutory approvals

Article 54.1 of the Tax Code is particularly important because it addresses the limits on reducing tax liabilities through distorted reporting of economic facts.

Taxpayers should ensure that research transactions are genuine, commercially justified and supported by reliable evidence.

False research invoices, fictitious laboratory expenditure and artificial intellectual property transactions can result in tax reassessments, penalties and, in serious cases, criminal liability under applicable Russian law.

16. Critical legal analysis

The Russian biotechnology taxation system presents several important legal questions.

First: Innovation versus taxation.

Biotechnology research requires significant investment and involves considerable scientific uncertainty. Article 262 provides a mechanism for recognising qualifying research expenditure, but compliance requirements can create administrative burdens.

Second: Classification of biotechnology activities.

A biotechnology enterprise may simultaneously conduct scientific research, pharmaceutical manufacturing, software development and intellectual property licensing. Different tax treatments may apply to each activity.

Third: VAT uncertainty.

The distinction between exempt research services, taxable commercial services and preferentially taxed pharmaceutical products requires careful legal classification.

Fourth: Unequal access to incentives.

Large pharmaceutical manufacturers and smaller biotechnology startups may have different capacities to satisfy the requirements for tax incentives, special economic zone residency and enhanced R&D deductions.

Fifth: International tax complications.

Cross-border licensing, technology transfers, research contracts and foreign investment create additional questions concerning withholding taxes, treaty benefits and transfer pricing.

Sixth: Future bioeconomy regulation.

The proposed 2026 bioeconomy roadmap raises the possibility of more targeted taxation measures. Whether these will become permanent statutory benefits will depend on subsequent legislative developments.

17. Conclusion

Biotechnology taxation law in Russia is primarily governed by the Russian Tax Code rather than a separate biotechnology taxation statute.

The most important legal provision for biotechnology research enterprises is Article 262, which establishes rules for recognising research and development expenditure and provides an enhanced deduction mechanism for qualifying projects.

Other important provisions include:

Article 149 — VAT exemptions.

Article 164 — VAT rates.

Article 148 — Place of supply of services.

Article 257 — Depreciable intangible assets.

Articles 105.1–105.3 — Transfer pricing.

Chapter 30 — Corporate property taxation.

Chapter 26.1 — Unified Agricultural Tax.

Russian judicial decisions concerning R&D expenditure, VAT exemptions and scientific service transactions provide important interpretative guidance.

The principal legal challenge is ensuring that biotechnology enterprises receive the tax treatment permitted by law while maintaining transparency, scientific accountability and proper financial documentation.

Overall, Russian biotechnology taxation is developing from a general corporate tax framework towards a more innovation-oriented system, with the proposed 2026 bioeconomy roadmap potentially creating additional sector-specific incentives.

18. Important legal research sources

For further academic and legal research, the following primary and institutional sources are useful:

Federal Tax Service of Russia — Official tax administration and guidance.

ConsultantPlus — Article 262, Tax Code.

OECD — Russia R&D tax incentives.

Presidium of the Supreme Arbitration Court, Resolution No. 16067/11.

Eighteenth Arbitration Appeal Court, Case No. 18АП-1052/2009.

Analysis of the TVEL and Materik VAT disputes.

Federal Tax Service: Tax changes for 2026.

2026 Russian bioeconomy taxation roadmap announcement.

Research note: This is an academic overview of the Russian legal framework as of 18 November 2026, not individual tax advice. The applicable consolidated legislation, transitional provisions and judicial decisions should be checked before relying on a particular tax benefit.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT